Since the analysis of this dataset in 2021, 2 accelerated FDA approvals of targeted therapies in 2022 and the respective supporting studies elevated the status of RET fusions and BRAF V600E mutation as actionable therapeutic markers with evidence of clinical significance across advanced solid tumors.53 Emerging biomarkers (eg, HRAS mutation in head and neck squamous cell carcinoma) may be actionable with only investigational approaches that are not approved yet. This evidence concerns the gene BRAF and head and neck squamous cell carcinoma.